ライフサイエンスコーパス: pharmacy

1 dication in the same medication class at any pharmacy).

2 y Compounding Accreditation Board-accredited pharmacy).

3 ndles larger quantities of the drug (e.g., a pharmacy).

4 repared in insulin syringes by a compounding pharmacy.

5 8 patients who received regorafenib from our pharmacy.

6 on between samples from the same compounding pharmacy.

7 ients receiving PN from a single compounding pharmacy.

8 mcinolone obtained from a single compounding pharmacy.

9 uating pharmacy students at 12 US schools of pharmacy.

10 r studying life processes in biomedicine and pharmacy.

11 1 year from 1 lot prepared by a compounding pharmacy.

12 mcinolone obtained from a single compounding pharmacy.

13 late in picking up their medication from the pharmacy.

14 that was purchased from a single compounding pharmacy.

15 rticoid medication from a single compounding pharmacy.

16 om syringes prepared by a single compounding pharmacy.

17 , which was prepared by the same compounding pharmacy.

18 o for 12 months) were dispensed by a central pharmacy.

19 one acetate prepared by a single compounding pharmacy.

20 bevacizumab prepared by the same compounding pharmacy.

21 methylprednisolone from a single compounding pharmacy.

22 uring syringe preparation by the compounding pharmacy.

23 s, adjusting for age, co-morbidities, and co-pharmacy.

24 ify previous or subsequent dispensing at any pharmacy.

25 ion, leading to antibiotic collection from a pharmacy.

26 applications in the fields of chemistry and pharmacy.

27 and may vary dramatically, depending on the pharmacy.

28 10% of antibiotics dispensed in UK community pharmacies.

29 ns dispensed during 2008 by 76% of US retail pharmacies.

30 by local, regional and national compounding pharmacies.

31 ent of adherence for patients who use retail pharmacies.

32 was purchased from four external compounding pharmacies.

33 mation on all prescriptions filled in Danish pharmacies.

34 heduled to present each case once to sampled pharmacies.

35 eceive prescription-only drugs directly from pharmacies.

36 a randomized trial conducted in 56 community pharmacies.

37 ations (1.31 cent/oz, p = 0.004), partial in pharmacies (+0.45 cent/oz, p = 0.03), and negative in in

38 nded samples of bevacizumab obtained from 11 pharmacies, 17 (81%) had lower protein concentrations (m

39 without insurance, price compare at multiple pharmacies; (3) use manufacturer-supplied coupons to red

40 r medical ($2684 vs $1980; P < .0001), lower pharmacy ($807 vs $1467; P < .0001), and greater overall

41 to 1.5%]) were subsequently dispensed by the pharmacy a mean of 1.0 (SD, 0.3) time during the 12-mont

42 illustrates the use of CAR-T cells as "micro-pharmacies" able to deliver an anti-cancer protein.

43 9 public, semiprivate (Karunya), and private pharmacies across 5 districts in Kerala using World Heal

44 re recruited in 2012-13 from community-based pharmacies across Australia.

45 ochemistry, molecular materials, biology and pharmacy, although it is certainly in coordination chemi

46 Pharmacy, ambulatory, and inpatient care collectively ac

47 tely compounded dry powder) and a variety of pharmacies (an academic hospital, a community hospital,

48 e better communication between providers and pharmacies and improve medication safety.

49 Under a scenario with 50% take-back to a pharmacy and 50% trash disposal, current API emissions a

50 From linked pharmacy and administrative databases of the New England

51 ts were ordered and purchased at an ordinary pharmacy and masked for blinding before the study was st

52 ween step therapy for antidepressants and 1) pharmacy and medical utilization and 2) spending.

53 papers were included, representing nursing, pharmacy and medicine from UK, Norway and USA.

54 Microarray technology, supported by pharmacy and microbiology departments, can decrease the

55 odes were available only to the MGH Research Pharmacy and not to study investigators or participants.

56 ol in New York City, Philadelphia College of Pharmacy and Science (now University of the Sciences) (B

57 supplements containing selenium bought in a pharmacy and supermarket.

58 l concentration in health systems, insurers, pharmacies, and benefit managers; (2) information techno

59 rivate efforts to combat illegitimate online pharmacies, and outlines strategies for physicians to re

60 ology, critical care, surgery, epidemiology, pharmacy, and adult and pediatric infectious diseases sp

61 tut fur Interdisziplinare Medizin), Burman's Pharmacy, and Kaiser Permanente Southern California.

62 Individual clinical, pharmacy, and laboratory data were merged using individu

63 , we used longitudinally linked demographic, pharmacy, and laboratory databases to examine correlates

64 Hospital, pharmacy, and mortality records between 1995 and 2015 we

65 ed information from the membership, medical, pharmacy, and surgical records from the electronic healt

66 ompany-not the manufacturer, distributor, or pharmacy-and is typically a co-pay, which is a fraction

67 uding the private sector--from workplaces to pharmacies--and with increased national and global inves

68 rious applications (i.e., in biomedicine and pharmacy, as thermo-responsive materials and energy tran

69 re and either the New Jersey or Pennsylvania pharmacy assistance program during 1994 to 2005, over 18

70 the annual costs (inpatient, outpatient, and pharmacy) associated with extrahepatic manifestations of

71 s of bevacizumab prepared by the compounding pharmacy at the same time as those prepared for the affe

72 unused syringes prepared by the compounding pharmacy at the same time.

73 scores significantly varied by the school of pharmacy attended.

74 to evaluate the effectiveness of a community pharmacy-based case finding and intervention on cardiova

75 In October 2010, the pharmacy began compounding and filter-sterilizing amino

76 nment including payor, prescriber specialty, pharmacy benefit manager, out-of-pocket cost (copay), cl

77 aried nearly 3-fold among the top 10 largest pharmacy benefit managers.

78 More aggressive management of pharmacy benefits for targeted oral anticancer medicatio

79 A subgroup of 9,027 with pharmacy benefits included 1,158 (12.8%) tobacco users.

80 omization, according to the Veterans Affairs Pharmacy Benefits Management database, were considered e

81 and Medicare databases, Tennessee Medicaid, pharmacy benefits plans for Medicare beneficiaries in Ne

82 The pharmacy benefits subgroup experienced 8,152 admissions.

83 illing codes were queried in a subgroup with pharmacy benefits.

84 Medicare fee-for-service coverage including pharmacy benefits.

85 scens BSIs in patients receiving PN from the pharmacy between January and March 2011.

86 ve cohort study using Medicaid encounter and pharmacy billing data from 29 US states between 1999 and

87 parations with applications in the fields of pharmacy, biomarker discovery, and protein biology.

88 omprise a significant proportion of hospital pharmacy budgets.

89 d access to 4 basic services (family doctor, pharmacy, cardiac rehabilitation, and pathology services

90 ge of antimicrobials was important for their pharmacy careers, and 89% desired more education on appr

91 Prescriptions bottled at the retail pharmacy chain between 1 July 2008 and 30 September 2008

92 uppressive medication use was defined as any pharmacy charge for a proton-pump inhibitor or histamine

93 Within LT patients, 60% did not have a pharmacy claim 45 days post-index; by 2 years, this redu

94 Pharmacy claim adherence, expressed as a percentage, was

95 the mean age for patients who had at least 1 pharmacy claim for narcotics within 1 month before surge

96 years and 41.1 years for patients without a pharmacy claim.

97 related hospitalization based on medical and pharmacy claims data and birth certificates.

98 Medical and pharmacy claims data between 2007 and 2012 were analyzed

99 stimated over 6-month rolling windows, using pharmacy claims data.

100 patients age >/= 18 years from a medical and pharmacy claims database for 14 commercial US health pla

101 abetes mellitus identified through visit and pharmacy claims during the observation period.

102 e, descriptive cohort study using nationwide pharmacy claims linked to electronic medical records fro

103 We examined the medical and pharmacy claims of a 20% sample of Medicare beneficiarie

104 ogen + androgen, as captured from outpatient pharmacy claims over a 4-year period.

105 hronic conditions were assessed with medical/pharmacy claims records and validated self-report scales

106 ge administrative database of US medical and pharmacy claims to identify a cohort of 105 269 patients

107 a (1987-2015) with records from a nationwide pharmacy claims warehouse (2005-2015) to examine prescri

108 needed to have at least two UC-specific non-pharmacy claims, at least 30 days of 5-ASA treatment and

109 glucocorticoids (GCs) were determined using pharmacy claims.

110 rence as the percentage of days "covered" by pharmacy claims.

111 al, a community hospital, and an independent Pharmacy Compounding Accreditation Board-accredited phar

112 d case patients' clinical records, evaluated pharmacy compounding practices, and obtained epidemiolog

113 Only some urban Indian pharmacies correctly managed patients with presumed tube

114 Pharmacy costs accounted for 28.4% of total direct medic

115 ts increased by $2952, reflecting the higher pharmacy costs of aliskiren and losartan ($7769), which

116 We based pharmacy costs on wholesale acquisition costs and based

117 The average monthly medical and pharmacy costs per person in the enhanced-support group

118 than offset these patients' expected higher pharmacy costs.

119 orders for medication discontinuation to the pharmacy, creating the potential for errors in dispensin

120 prescribed at discharge were abstracted from pharmacy data and converted into OME.

121 ned via medical record review and electronic pharmacy data at diagnosis and within 6 months after dia

122 ICS and ICS/LABA exposure was estimated from pharmacy data for patients with asthma aged 12 to 56 yea

123 ns were submitted for 51 466 patients in the pharmacy data set.

124 Clinical and pharmacy data were collected, and a patient questionnair

125 cal characteristics, laboratory results, and pharmacy data were extracted from the VA electronic medi

126 Pharmacy data were used to identify medications that wer

127 mation System database using ICD-9 codes and pharmacy data.

128 s diagnostic codes along with laboratory and pharmacy data.

129 ose over the previous 90 days from automated pharmacy data.

130 telet-ASA) were identified from the national pharmacy database (October 1, 2002 to September 30, 2008

131 ronic search of the Kaiser Permanente Hawaii pharmacy database for Generic Product Identification cod

132 rmed a retrospective analysis of a community pharmacy database from The Netherlands containing data f

133 ram database and the Decision Support System pharmacy database were linked to analyze the association

134 entation in the hospital medical records and pharmacy database.

135 hiopurine exposure was assessed using the VA pharmacy database.

136 scriptions were determined from the national pharmacy database.

137 bodies were identified using the Mayo Cancer Pharmacy Database.

138 n dosage was determined according to the NHI pharmacy database.

139 Patients were identified through a pharmacy database.

140 the study period, 45 were identified in the pharmacy database: 62% women, 84% white, and 80% relativ

141 and in late life (mean age, 76 years) using pharmacy databases from 1994 to 1998.

142 ans Administration National Patient Care and Pharmacy databases were used to extract patient characte

143 07-14), we linked administrative custody and pharmacy databases with mandatory HIV/AIDS surveillance

144 beta2-agonists) were extracted from 65 Dutch pharmacy databases, representing 3% of the population (5

145 hium exposure (n = 11,317) was assessed from pharmacy databases, serum lithium levels were obtained f

146 S) was based on clinical trial registries or pharmacy databases.

147 2,073 air samples obtained from compounding pharmacies, demonstrated that the YMEA yielded >2.5 time

148 individual health professions (ie, nursing, pharmacy, dentistry, and dietetics) and offers suggestio

149 Retail pharmacies dispensed 255291 antibiotics to this cohort i

150 No pharmacy dispensed anti-tuberculosis drugs for either ca

151 Electronic health records and pharmacy dispensing data were reviewed for 90 patients w

152 ioners' records, hospital discharge letters, pharmacy dispensing data, and serum fasting glucose meas

153 We collected clinical data and pharmacy dispensing records on patients taking 8, 12, or

154 Information on pharmacy dispensing was available for only 52% of medica

155 n (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combi

156 use of 1-12 years' duration, determined from pharmacy dispensings.

157 Most students (84%) considered their pharmacy education regarding antimicrobials useful or ve

158 hylprednisolone acetate were recalled by the pharmacy; examination of unopened vials later revealed f

159 We defined ART initiation as the first pharmacy fill date of a qualifying ART regimen of >/=3 d

160 of Transplant Recipients were linked to IMS pharmacy fills (January 1, 2001 to October 1, 2012) to i

161 Bevacizumab acquired from compounding pharmacies for intravitreal injection may cause infectio

162 ted with use of more prescribers and/or more pharmacies for obtaining prescription opioids.

163 ical advice and drug dispensing practices of pharmacies for standardised patients with presumed and c

164 istration (36%), and referring patients to a pharmacy for vaccine administration (33%).

165 th use of sales data for retail and hospital pharmacies from the IMS Health MIDAS database, we review

166 onverting enzyme inhibitors, and statins) in pharmacies gathered from 596 communities in 18 countries

167 Repackaged bevacizumab from the compounding pharmacies had a wide range of particle counts (89,006 +

168 e study statistician and the investigational pharmacy had the preset randomisation assignments.

169 methylprednisolone produced by a compounding pharmacy has resulted in >750 infections.

170 ed by Canadian guidelines) through community pharmacies, hospitals, or primary care teams in 23 commu

171 icals: (i) incineration after take-back to a pharmacy, (ii) wastewater treatment after toilet disposa

172 ector hospitals and 36 private sector retail pharmacies in 2010 and 72 public hospitals and 72 retail

173 n 2010 and 72 public hospitals and 72 retail pharmacies in 2012.

174 il 1, 2014, and Nov 29, 2015, we sampled 622 pharmacies in Delhi, Mumbai, and Patna.

175 of hospitalization and drug dispensing from pharmacies in Denmark.

176 s were distributed to clinics and dispensing pharmacies in Shimane and Hiroshima prefectures.

177 ion of repeated PPI and H2B dispensations at pharmacies in Sweden allowed modeling the time-dependent

178 ich includes approximately 60% of all retail pharmacies in the United States.

179 ich includes approximately 60% of all retail pharmacies in the United States.

180 ory, microbiology, pathology, radiology, and pharmacy information systems.

181 edical records of laboratory, diagnosis, and pharmacy information.

182 Use of multiple prescribers and pharmacies is a means by which some individuals misuse o

183 , and more rigorous oversight of compounding pharmacies is needed to prevent future outbreaks.

184 he only preparation stocked by many hospital pharmacies, is prescribed routinely for treatment of hyp

185 and outcomes were ascertained via electronic pharmacy, laboratory, and diagnostic databases.

186 cost, and ambulatory cost and its subtypes (pharmacy, laboratory, and radiology).

187 price increase, suggesting that clinician or pharmacy level interventions could potentially increase

188 cal care, medicine, respiratory therapy, and pharmacy; mean number of nonsurgical participants/sessio

189 p programs (ASPs) to more efficiently review pharmacy, microbiology, and clinical data.

190 e for preparing the study treatments and the pharmacy monitor at each site.

191 ion medicine was available at 63% of private pharmacies (n=109) and 27% of Karunya (semiprivate) phar

192 ies (n=109) and 27% of Karunya (semiprivate) pharmacies (n=22).

193 Inc., which maintains an electronic audit of pharmacies nationwide.

194 July 2014 Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the

195 An FDA investigation of the compounding pharmacy noted deviations from standard sterile techniqu

196 egration into primary health care (medicine, pharmacy, nursing, and allied health science professions

197 standard-dose vaccines in community-located pharmacies offering both vaccines.

198 Compounding pharmacies often prepare parenteral nutrition (PN) and m

199 lished in the subject areas of pharmacology, pharmacy, oncology, and medicinal chemistry.

200 ), and those filled at a specialty vs retail pharmacy (OR, 1.96; 95% CI, 1.66-2.33).

201 ection of an oral HIVST from a health clinic/pharmacy), or (3) standard-of-care HIV testing.

202 Patients sought treatment in pharmacies, or with traditional healers who had differen

203 er-generated, and allocation was assigned by pharmacy personnel who prepared intervention and placebo

204 ation, maintained and concealed centrally by pharmacy personnel, was computer-generated using fixed b

205 atabase that is part of the population-based pharmacy prescription InterAction Database from the nort

206 overall (P <0.0001) and 71% more UC-related pharmacy prescriptions (P <0.0001) than did nonadherent

207 Adherent patients had 25% more pharmacy prescriptions overall (P <0.0001) and 71% more

208 its evaluation by practicing pharmacists and pharmacy professors and its repeated use in training pha

209 H (Alberta Vascular Risk Reduction Community Pharmacy Project) study was a randomized trial conducted

210 Pharmacy purchasing data underestimated cost savings com

211 or a total yearly cost savings of $54656 for pharmacy purchasing data, $1184336 for EMR data, and $21

212 pectively assessed anti-infective cost using pharmacy purchasing data, patient-level administration d

213 Pharmacy purchasing endorsed minimal financial benefit (

214 rapy, surgery, and support services, such as pharmacy, radiology, laboratory, and counselling) at Hop

215 ions, the rate of subsequent dispensing by a pharmacy ranged from 0.9% for metformin to 2.5% for meto

216 Four national chain pharmacies received surveys requesting price data on com

217 information was ascertained from electronic pharmacy records and analyzed using conditional logistic

218 h 1, 2013, and July 15, 2015, via electronic pharmacy records and departmental databases at three ins

219 ntinuously for at least 5 years according to pharmacy records and who were evaluated with visual fiel

220 reviewing filled prescriptions in electronic pharmacy records during a 10-year period before the Barr

221 ormation on medication use was compared with pharmacy records for statins, calcium channel blockers,

222 sic prescription rates were much higher than pharmacy records indicate, with self-reported prescribin

223 Hospital pharmacy records indicated the preferential use of amika

224 zed trials, and multiple recent studies with pharmacy records indicates that the delivery of OMT is f

225 tion period were ascertained by linkage with pharmacy records through the national health insurance s

226 Detailed electronic medical and pharmacy records were analyzed to explore the associatio

227 integrated national US transplant registry, pharmacy records, and Medicare claims data for 16 308 ki

228 Compared with pharmacy records, self-reported information on current m

229 Compared with pharmacy records, the sensitivity, specificity, and PPV

230 etes medications as captured from outpatient pharmacy records.

231 on information were collected by medical and pharmacy records.

232 was defined using public medical, legal, or pharmacy records.

233 disease was identified using these codes and pharmacy records.

234 h Revision, Clinical Modification codes, and pharmacy records; incident tuberculosis disease was iden

235 e was measured for each patient by obtaining pharmacy refill data and calculating medication possessi

236 cohol use disorder in medical, criminal, and pharmacy registries was assessed in a population-based S

237 use was assessed from medical, criminal, and pharmacy registries.

238 UD was assessed using medical, criminal, and pharmacy registries.

239 der was assessed from medical, criminal, and pharmacy registries.

240 use disorder recorded in medical, legal, or pharmacy registry records.

241 Drug abuse recorded in medical, legal, or pharmacy registry records.

242 Drug abuse recorded in medical, legal, or pharmacy registry records.

243 S: Drug abuse recorded in medical, legal, or pharmacy registry records.

244 mpling for bacteria and fungi in compounding pharmacies require the use of a medium for each type of

245 All-cause medical and pharmacy resource utilization and costs were computed ov

246 Patients were most often referred to pharmacies/retail stores and public health departments.

247 r (May 1 to July 30, 2013) the Ohio Board of Pharmacy's requirement of PSPs for bevacizumab.

248 Although pharmacy sales of OTC syringes are associated with reduc

249 ; 95% confidence interval, 1.01-1.03) higher pharmacy sales rate from 2005 through 2009, although thi

250 the IMS Health National Prescription Audit (pharmacy sales), and the MarketScan Commercial Claims da

251 escriptions for advertised products based on pharmacy sales; (2) prescription claims for asthma medic

252 predictors of a higher knowledge score were pharmacy school attended, planned postgraduate training,

253 tation in infectious diseases, perception of pharmacy school education as useful, use of resources to

254 ndertook two public (hospitals) and private (pharmacy) sector surveys of prices and availability of m

255 Expansion of clinical pharmacy services is often impeded by policy, legislatio

256 alyses, highlighting the benefit of clinical pharmacy services, are summarized.

257 t outpatients; and radiology, pathology, and pharmacy services.

258 Seventy-one hospitals (76%) had any pharmacy services.

259 edicine screening program in urban clinic or pharmacy settings in the United States serving predomina

260 INSIGHT]) was conducted at 4 urban clinic or pharmacy settings in the United States serving predomina

261 a from IntrinsiQ Intellidose data systems, a pharmacy software provider maintaining a population-base

262 ma control, or speak with an asthma nurse or pharmacy staff member.

263 Participants, physicians, and pharmacy staff were masked to group assignment.

264 rapid organism identification and dedicating pharmacy stewardship personnel time on the total hospita

265 of implementing MALDI-TOF and of dedicating pharmacy stewardship personnel time to interventions, th

266 Pharmacy stockouts could not be calculated at this site.

267 the desired target for on-time pill pickup, pharmacy stockouts, and virological suppression.

268 nd resistance was administered to graduating pharmacy students at 12 US schools of pharmacy.

269 Pharmacy students perceive antimicrobial stewardship to

270 Of 1445 pharmacy students, 579 (40%) completed the survey.

271 lectronic database compiled from laboratory, pharmacy, surgery, financial, and patient location and d

272 the number of prescribers and the number of pharmacies that an individual used during a single year

273 walk-in clinics located in retail stores or pharmacies that are typically staffed by nurse practitio

274 e to repackaging processes undertaken by the pharmacies that compound these agents.

275 ssociated with the number of prescribers and pharmacies that individuals used for prescription opioid

276 nactivated influenza vaccines from community pharmacies that offered both vaccines during the 2012-13

277 Among the 75 pharmacies that stocked cessation medications, 96% had n

278 eport by the FDA based on site visits to the pharmacy that prepared the bevacizumab syringes was summ

279 must assure that services such as radiology, pharmacy, the laboratory, and information services are p

280 also compiled a comprehensive list of retail pharmacies, their location, and whether they sell OTC sy

281 e obtained from all outpatient and inpatient pharmacies throughout Sweden.

282 reaks should focus on the procedures used by pharmacies to compound bevacizumab.

283 their offices (49%), referring patients to a pharmacy to purchase the vaccine and bring it back to th

284 Using pharmacy transaction data, we evaluated 45029 patients w

285 ystems for medication provision in community pharmacies; triage processes to enable effective and tim

286 ity and subgroup analyses by insurance type, pharmacy type, sex, and indication identified similar as

287 ncidence rates of new prescriber use and new pharmacy use for opioid prescriptions declined across in

288 incidence rate of new prescriber use and new pharmacy use than females.

289 S. marcescens was identified from a pharmacy water faucet, mixing container, and opened amin

290 on all drugs dispensed from community-based pharmacies were assembled.

291 Studies set in retail pharmacies were excluded.

292 ons of bevacizumab acquired from compounding pharmacies were negative for microbial contaminants and

293 Hospital pharmacies were responsible for preparing, blinding, and

294 rmy career, criminal justice, and medical or pharmacy) were used to predict suicides in the subsequen

295 ector, private-sector facilities, especially pharmacies, were not widely accessed for tuberculosis di

296 available if they were present in the local pharmacy when surveyed, and affordable if their combined

297 were considered available if present at the pharmacy when surveyed, and affordable if their combined

298 In 3 of 10 compounding pharmacies where more than 1 sample was available, there

299 on seems to have occurred at the compounding pharmacy, where numerous problems in sterile technique w

300 tts General Hospital (MGH) Clinical Research Pharmacy with a permuted-block algorithm, stratified by